Keywords: Nilotinib; Lithium; Cell death; Autophagy; Bcr-Abl; GSK-3β; Clonogenicity; Leukemia cells;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: 5-FU; 5-fluorouracil; AF; atrial fibrillation; ALK; anaplastic lymphoma kinase; APD; action potential duration; APL; acute promyelocytic leukemia; BCR-ABL; breakpoint cluster region-Abelson; BTK; Bruton tyrosine kinase; CD20; cluster of differentiation 20
Keywords: ALK; anaplastic lymphoma kinase; ATP; adenosine triphosphate; BCR-ABL; Breakpoint cluster region-Abelson; DMEM; Dulbecco Modified Eagle Medium; EGFR; epidermal growth factor receptor; FUCCI; Fluorescence Ubiquitination Cell Cycle Indicator; HER; human e
Keywords: Allogeneic stem cell transplantation; BCR-ABL; chronic myeloid leukaemia; dasatinib; imatinib; nilotinib; Philadelphia chromosome; ponatinib; quantitative RT-PCR; tyrosine kinase inhibitors;
Keywords: Ankle-brachial index; BCR-ABL; Cardiovascular disease; Peripheral arterial disease; Tyrosine kinase inhibitor;
Keywords: cabozantinib; depigmentation; dyspigmentation; hyperpigmentation; hypopigmentation; imatinib; ipilimumab; nivolumab; pazopanib; pembrolizumab; pigmentary; repigmentation; sorafenib; sunitinib; vitiligo; AE; adverse event; Bcr-abl; breakpoint cluster regio
Keywords: Chronic myeloid leukemia; Tyrosine kinase Inhibitor; Imatinib; BCR-ABL; Molecular response;
Keywords: Tyrosine kinase inhibitor; Acute myeloid leukemia; Myeloproliferative neoplasms; BCR-ABL; JAK2; Calreticulin; FLT3; Oncogene addiction;
Keywords: BCR-ABL; Disease outcome; Molecular monitorization; Progression-free survival; Tyrosine kinase inhibitors;
Keywords: Adverse events; Age; BCR-ABL; Large granular lymphocyte; Tyrosine kinase inhibitor;
Keywords: AAA; ATPases associated with diverse cellular activities; 17-AAG; 17-N-allylamino-17-demethoxygeldanamycin; ABC; ATP-binding cassette; ABCE1; ATP binding cassette subfamily E member 1; AD; Alzheimer's disease; AIF; apoptosis inducing factor; Akt; Alpha se
Keywords: Acute lymphoblastic leukemia; Allogeneic transplantation; BCR-ABL; Philadelphia chromosome; Stem cell transplantation;
Keywords: adverse sequelae; alopecia; antiangiogenic agents; anticancer; BCR-ABL; bevacizumab; cancer treatment; canertinib; cetuximab; chemotherapy; cutaneous adverse effects; dasatinib; dermatologic toxicities; disturbed wound healing; drug eruption; drug rash; d
Keywords: BCR-ABL; breakpoint cluster region-Abelson tyrosine-protein kinase; CD95/FAS; cluster of differentiation 95/cell surface death receptor; DDR1; discoidin domain receptor tyrosine kinase 1; EGFR; epidermal growth factor receptor tyrosine kinase; EF1A2; euka
BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562â¯cells
Keywords: BCR-ABL; Integrated stress response; PERK; GCN2; ATF4;
Analysis of ABL kinase domain mutations as a probable cause of imatinib resistance in Chronic Myeloid Leukemia patients of Kashmir
Keywords: Imatinib resistance; Fusion transcript; Kinase domain; cDNA; BCR-ABL; Complete cytogenetic response;
New rapid method to detect BCR-ABL fusion genes with multiplex RT-qPCR in one-tube at a time
Keywords: Leukemia; BCR-ABL; Multiplex RT-qPCR; Fish; Minimal residual disease;
Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells
Keywords: Chronic myelogenous leukemia; Checkpoint kinase 1; Bcr-Abl; Drug resistance;
Re-evaluating the role of FOXOs in cancer
Keywords: RTK; receptor tyrosine kinase; GF; growth factor; PI3K; Phosphatidylinositol-4,5-bisphosphate 3-kinase; PKB; protein kinase B; AKT; RAC-alpha serine/threonine-protein kinase; FOXO; forkhead box O; GFR; growth factor receptor; PDPK1; Phosphoinositide-depen
Autophagy enhanced antitumor effect in K562 and K562/ADM cells using realgar transforming solution
Keywords: Realgar transforming solution; Autophagy; Apoptosis; Bcr-Abl; Multidrug-resistant;
siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo
Keywords: BCR-ABL; Chronic myeloid leukemia (CML); Fusion gene; Gene therapy; Lypopolymer carrier; Non-viral delivery; RNAi; siRNA delivery;
Bach2 regulates aberrant activation of B cell in systemic lupus erythematosus and can be negatively regulated by BCR-ABL/PI3K
Keywords: Systemic lupus erythematosus (SLE); Bach2; BCR-ABL; PI3K; B cells;
Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia
Keywords: Chronic myeloid leukemia; JAK inhibitor; BCR-ABL; Tofacitinib; Imatinib;
ROS signalling in the biology of cancer
Keywords: AEJ; alternative end joining; ALL; acute lymphoblastic leukaemia; AML; acute myeloid leukaemia; Apaf-1; apoptotic protein activating factor 1; APL; acute promyelocytic leukaemia; ASK1; apoptosis signal regulating kinase 1; Bcr-Abl; breakpoint cluster-Abel
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines
Keywords: HO-1 inhibitors; Tyrosine kinase inhibitors; BCR-ABL; Imatinib; Chronic myeloid leukemia;
Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation
Keywords: ABL; Abelson murine leukemia viral oncogene homolog 1; ALIS; aggresome-like induced structure; ALL; acute lymphoblastic leukemia; BCR; breakpoint cluster region; CML; chronic myeloid leukemia; DCFH-DA; 2â², 7â²-dichlorodihydrofluorescein diacetate; DCPI
Autophagy as a pharmacological target in hematopoiesis and hematological disorders
Keywords: 3-MA; 3-methyladenine; ALL; acute lymphoblastic leukemia; AMKL; acute megakaryoblastic leukemia; AML; acute myeloid leukemia; AMPK; 5â²-adenosine monophosphate-activated protein kinase; APL; acute promyelocytic leukemia; Atg; autophagy-related proteins;
SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia
Keywords: Imatinib mesylate (PubChem CID: 123596); Dasatinib (PubChem CID: 3062316); Ponatinib (PubChem CID: 24826799); Nilotinib (PubChem CID: 644241); SHC004-221A1; Chronic myeloid leukemia (CML); BCR-ABL; T315I mutation;
siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model
Keywords: Chronic myeloid leukemia; Bcr-Abl; siRNA; Dengue virus capsid protein; Cell-penetrating peptide; Bioportide; Microarray;
Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents
Keywords: MDR; BCR-ABL inhibitors; EGFR inhibitors; VEGFR inhibitors; Drug combinations; ABC; ATP binding cassette; ADME-tox; absorption, distribution, metabolism, excretion, toxicity; AKT; v-akt murine thymoma viral oncogene homolog; ALL; acute lymphoblastic leuke
In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I mutant and wild-type BCR-ABL1: A virtual screening and molecular dynamics study
Keywords: Chronic Myeloid Leukemia; BCR-ABL; Drug repurposing; Docking; Molecular dynamic simulations;
Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand
Keywords: BCR-ABL; Bestatin; Imatinib; E3 ubiquitin ligase; Protein knockdown;
A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant
Keywords: Bcr-Abl; T315I; Allosteric; Myristate; Kinase; Leukemia; Resistance
Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma
Keywords: ALL; acute lymphoblastic leukemia; BCR-ABL; breakpoint cluster region-Abelson murine leukemia viral oncogene homolog; CML; chronic myeloid leukemia; CYP3A4; cytochrome P450 3A4; DMP; N-desmethyl ponatinib; ESI; electrospray Ionization; FVB; friend leukemi
MEF2C and CEBPA: Possible co-regulators in chronic myeloid leukemia disease progression
Keywords: BCR-ABL; CML; MEF2C; CEBPA; Imatinib; K562
Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells
Keywords: SBF-1; Chronic myeloid leukemia; Imatinib; Bcr-Abl; PTP1B;
NCCN and ELN: What do the guidelines tell us?
Keywords: Chronic Myeloid Leukemia; BCR-ABL; Tyrosine kinase inhibitors; NCCN; ELN;
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia
Keywords: BCR-ABL; Drug toxicity; Recurrent adverse event; Treatment discontinuation; Tyrosine kinase inhibitor;
Original ArticlePBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia
Keywords: PBA2; Chronic myeloid leukemia; BCR-ABL; T315I; Resistance;
Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells
Keywords: Imatinib; Cisplatin; Oxaliplatin; Bcr-Abl; DNA damage
Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells
Keywords: Adiponectin; Adiponectin Receptor; Chronic myeloid leukemia; Imatinib; Resistance; Bcr-Abl;
CCR7 is involved in BCR-ABL/STAP-2-mediated cell growth in hematopoietic Ba/F3 cells
Keywords: CML; BCR-ABL; STAP-2; CCR7; MAPK/ERK;
ABL SH3 mutant inhibits BCR-ABL activity and increases imatinib sensitivity by targeting RIN1 protein in CML cell
Keywords: Chronic myeloid leukemia; BCR-ABL; SH3 domain; RIN1;
1,3-Butadiene, CML and the t(9:22) translocation: A reality check
Keywords: t(9:22); BCR-ABL; Radiation; HL60; 1,3-Butadiene; CML;
Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1
Keywords: Chronic myeloid leukemia; Imatinib; Divalproex sodium; Bcr-Abl; SIRT1;
Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine
Keywords: Bcr-Abl; Hinge-binding fragment; ATP-Binding site; Flexible linker; Resistance;
Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia
Keywords: Fatty-acid derivative; Autophagy; Bcr-abl; Cell death; Warburg effectCML, chronic myeloid leukemia; mTOR, mammalian target of rapamycin; TKI, tyrosine kinase inhibitor; hnRNP, heterogenous nuclear ribonucleoprotein; PKM, pyruvate kinase M; STAT3, signalin
Incidence and risk of xerosis with targeted anticancer therapies
Keywords: Bcr-Abl; CD20; CD52; dry skin; EGFR; HDAC; HER2; incidence; MEK; mTOR; Raf; risk; xerosis; VEGFRADL, activities of daily living; AE, adverse event; CI, confidence interval; CTCAE, Common Terminology Criteria for Adverse Events; dAE, dermatologic adverse e
Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia
Keywords: Acute biphenotypic leukemia; Adult; BCR-ABL; Survival analysis